Trial | NCT01919710  Report issue

Title

Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    Cancer Tumor ...

  • Study Participants

    29
Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.
A dosage climbing for the safety and efficacy studies for the neutropenia induced by chemotherapy cancer patients Repeat-dose studies for the safety and efficacy studied for the neutropenia.
Study Started
Oct 31
2012
Primary Completion
Jun 30
2014
Study Completion
Aug 31
2014
Last Update
Jun 03
2015
Estimate

Drug rHSA/GCSF

for treatment of neutropenia

  • Other names: Long acting rhG-CSF fusion protein

rHSA/GCSF for injection Experimental

rHSA/GCSF Start from 300mcg

Criteria 

Inclusion Criteria:

- chemotherapy induced neutropenia

Exclusion Criteria:

- treated with other biological drugs or other neutropenia therapy drugs
No Results Posted